Related Experiment Videos
Personalized Therapy: Tumor Antigen Discovery for Adoptive Cellular Therapy
1From The University of Texas MD Anderson Cancer Center, Houston, TX.
Cancer Journal (Sudbury, Mass.)
|April 15, 2017
Summary
Adoptive cell therapy with endogenous T cells offers a streamlined approach for antigen discovery and validation. This method bypasses tumor requirements and engineering complexities, enabling rapid clinical translation for cancer immunotherapy.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Adoptive cell therapy (ACT) is a promising cancer treatment.
- Current ACT methods often rely on genetically engineered T cells or tumor-infiltrating lymphocytes.
- These approaches face regulatory and logistical challenges.
Purpose of the Study:
- To highlight the advantages of using endogenous T cells for ACT.
- To demonstrate the utility of endogenous T-cell therapy in validating tumor antigens.
- To present endogenous T-cell therapy as a rapid and adaptable clinical strategy.
Main Methods:
- Ex vivo isolation and expansion of antigen-specific T cells from peripheral blood.
- Utilizing candidate epitope peptides identified through antigen discovery as therapeutic targets.
- Employing first-in-human studies with defined T-cell populations to assess antigen efficacy.
Main Results:
- Endogenous T-cell therapy does not require accessible tumor tissue.
- This approach circumvents regulatory and logistical hurdles associated with engineered T cells.
- Adoptively transferred T cells serve as a transferable cellular biomarker to evaluate treatment outcomes.
Conclusions:
- Endogenous T-cell therapy is a powerful tool for validating tumor rejection antigens.
- It facilitates rapid clinical trials and personalized treatment strategies.
- This method offers a flexible and efficient pathway for advancing cancer immunotherapy.